Dyne Therapeutics 

Yahoo Finance • 2 days ago

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 3 days ago

Why Analysts See a Huge Upside for Dyne Therapeutics (DYN)

Dyne Therapeutics (NASDAQ:DYN) is one of the most promising mid-cap healthcare stocks under $50. As of the December 19 closing, the consensus analyst sentiment towards Dyne Therapeutics (NASDAQ:DYN) remains bullish. After a decline of alm... Full story

Yahoo Finance • 14 days ago

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 15 days ago

Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Oppenheimer upgraded GE Vernova(GEV) t... Full story

Yahoo Finance • 16 days ago

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 16 days ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 16 days ago

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Key Points Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter. Saturn V now holds 4.6 million... Full story

Yahoo Finance • 16 days ago

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Key Points Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn V now holds nearly 2.7 mill... Full story

Yahoo Finance • 17 days ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 17 days ago

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previou... Full story

Yahoo Finance • 18 days ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics, Inc. Loss At -$108.14 Mln In Q3

(RTTNews) - Dyne Therapeutics, Inc. (DYN) revealed Loss for third quarter of -$108.14 million The company's earnings came in at -$108.14 million, or -$0.76 per share. This compares with -$97.12 million, or -$0.96 per share, last year. D... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 20... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 2 months ago

Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger

We recently published 10 Big Names Crushing Wall Street. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the top-performing stocks on Monday. Dyne Therapeutics soared by 41.18 percent on Monday to close at $24.17 apiece following a comment... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more

Check out the companies making the biggest moves midday: Qualcomm — The chipmaker soared more than 11% after announcing artificial intelligence processors to compete with AMD and Nvidia . The AI chips are a shift for Qualcomm , which has p... Full story

Yahoo Finance • 2 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

JHVEPhoto / Getty Images Avidity Biosciences is being bought by Novartis in a $12 billion deal. Key Takeaways Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments fo... Full story

Yahoo Finance • 2 months ago

Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal

Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 bill... Full story

Yahoo Finance • 2 months ago

Jefferies sees Dyne as key beneficiary of Novartis’ Avidity buyout

Investing.com -- Dyne Therapeutics is positioned as a major beneficiary of Novartis’ $12 billion acquisition of Avidity Biosciences, Jefferies analysts said, calling the deal a strong validation of RNA-based therapies for rare muscle disea... Full story

Yahoo Finance • 3 months ago

Dyne cut to Perform at Oppenheimer on valuation

[Wall Street New York stock exchange stock market] alexsl Shares of Dyne Therapeutics (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]) fell on Friday after Oppenheimer downgraded the neuromuscular disease company to Perform from Outperf... Full story